首页 > 最新文献

中华男科学杂志最新文献

英文 中文
[Analysis of transurethral water vapor thermal therapy for the treatment of benign prostatic hyperplasia]. 【经尿道水蒸汽热疗治疗良性前列腺增生分析】。
Q4 Medicine Pub Date : 2025-07-01
Ming-Yang Pang, Yong Wei, Jian-Zhong Lin, Jun Wang, Ming-Yu Liu, Fu-Yang Liu, Yi-Bo Ma, Tong Zhao, Qing-Yi Zhu

Objective: To investigate the efficacy and safety of transurethral water vapor thermal therapy (WVTT) using the Rezūm system for benign prostatic hyperplasia (BPH) in the real world.

Methods: A total of 181 patients with BPH were recruited from the Second Affiliated Hospital of Nanjing Medical University from August 2022 to December 2023, of whom 173 patients were treated with WVTT using the Rezūm system, while 8 patients were treated with WVTT combined with TURP. They were followed up at 1, 3, and 6 months postoperatively to assess changes in the IPSS, QoL, Qmax, IIEF-5, and the occurrence of any complications. Results: All 181 surgeries in this group were successfully completed. The operation time of the Rezūm system was (4.6 ± 1.4) minutes. The postoperative indwelling catheterization time was (8.0 ± 2.1) days. With a follow-up of at least 6 months, there was a significant decrease in PV, IPSS and QoL, and a remarkable increase had been found in Qmax as well (P<0.05). There was no significant difference in IIEF-5 before and after the operation (P>0.05). In this groups of patients, postoperative complications mainly included 95 cases (52.5%) of gross hematuria, 6 cases (3.3%) of retrograde ejaculation, 5 cases (2.8%) of urethral stricture, 4 cases (2.2%) of prostatitis, and 10 cases (5.5%) of urinary tract infection. Four cases (2.2%) underwent surgical retreatment for BPH after surgery.

Conclusion: In the real world, the use of Rezūm thermal steam ablation system for the treatment of BPH has satisfactory short-term effect, short surgical time, and significant improvement in IPSS, QoL, Qmax, which does not adversely affect sexual function.

目的:探讨Rezūm系统经尿道水蒸汽热疗法(WVTT)治疗前列腺增生症(BPH)的临床疗效和安全性。方法:于2022年8月至2023年12月在南京医科大学第二附属医院招募BPH患者181例,其中173例采用Rezūm系统进行WVTT治疗,8例采用WVTT联合TURP治疗。分别于术后1、3、6个月进行随访,评估IPSS、QoL、Qmax、IIEF-5的变化及并发症发生情况。结果:本组181例手术均顺利完成。Rezūm系统运行时间为(4.6±1.4)分钟。术后留置导尿时间为(8.0±2.1)d。随访至少6个月后,两组患者PV、IPSS、QoL均显著降低,Qmax均显著升高(P0.05)。本组患者术后并发症主要为总血尿95例(52.5%)、逆行射精6例(3.3%)、尿道狭窄5例(2.8%)、前列腺炎4例(2.2%)、尿路感染10例(5.5%)。4例(2.2%)术后再手术治疗BPH。结论:在现实生活中,应用Rezūm热蒸汽消融系统治疗BPH短期效果满意,手术时间短,IPSS、QoL、Qmax均有明显改善,且对性功能无不良影响。
{"title":"[Analysis of transurethral water vapor thermal therapy for the treatment of benign prostatic hyperplasia].","authors":"Ming-Yang Pang, Yong Wei, Jian-Zhong Lin, Jun Wang, Ming-Yu Liu, Fu-Yang Liu, Yi-Bo Ma, Tong Zhao, Qing-Yi Zhu","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy and safety of transurethral water vapor thermal therapy (WVTT) using the Rezūm system for benign prostatic hyperplasia (BPH) in the real world.</p><p><strong>Methods: </strong>A total of 181 patients with BPH were recruited from the Second Affiliated Hospital of Nanjing Medical University from August 2022 to December 2023, of whom 173 patients were treated with WVTT using the Rezūm system, while 8 patients were treated with WVTT combined with TURP. They were followed up at 1, 3, and 6 months postoperatively to assess changes in the IPSS, QoL, Qmax, IIEF-5, and the occurrence of any complications. Results: All 181 surgeries in this group were successfully completed. The operation time of the Rezūm system was (4.6 ± 1.4) minutes. The postoperative indwelling catheterization time was (8.0 ± 2.1) days. With a follow-up of at least 6 months, there was a significant decrease in PV, IPSS and QoL, and a remarkable increase had been found in Qmax as well (P<0.05). There was no significant difference in IIEF-5 before and after the operation (P>0.05). In this groups of patients, postoperative complications mainly included 95 cases (52.5%) of gross hematuria, 6 cases (3.3%) of retrograde ejaculation, 5 cases (2.8%) of urethral stricture, 4 cases (2.2%) of prostatitis, and 10 cases (5.5%) of urinary tract infection. Four cases (2.2%) underwent surgical retreatment for BPH after surgery.</p><p><strong>Conclusion: </strong>In the real world, the use of Rezūm thermal steam ablation system for the treatment of BPH has satisfactory short-term effect, short surgical time, and significant improvement in IPSS, QoL, Qmax, which does not adversely affect sexual function.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 7","pages":"603-607"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research progress on improving stem cell treatment of erectile dysfunction]. 【干细胞治疗勃起功能障碍的研究进展】。
Q4 Medicine Pub Date : 2025-07-01
Jie Huang, Kang Zhou, Jian-Xiong Ma, Bo-Dong Lü

Stem cells therapy is an emerging method for the treatment of erectile dysfunction (ED) in men. Compared with traditional treatment, it has the advantage lies in the ability to treat the pathological damage of the penis in patients with ED, which provides new ideas for solving erectile dysfunction fundamentally. However, due to the special anatomical structure of the penis, the therapeutic effect of stem cells is sometimes unsatisfactory. Therefore, how to improve the effect of stem cells therapy for ED has become a new difficulty. Relevant researches on how to improve stem cell treatment of ED will be reviewed in this article.

干细胞治疗是治疗男性勃起功能障碍(ED)的一种新兴方法。与传统治疗方法相比,其优势在于能够治疗ED患者阴茎的病理性损伤,为从根本上解决勃起功能障碍提供了新的思路。然而,由于阴茎特殊的解剖结构,干细胞的治疗效果有时并不理想。因此,如何提高干细胞治疗ED的效果成为一个新的难点。本文将对干细胞治疗ED的相关研究进行综述。
{"title":"[Research progress on improving stem cell treatment of erectile dysfunction].","authors":"Jie Huang, Kang Zhou, Jian-Xiong Ma, Bo-Dong Lü","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Stem cells therapy is an emerging method for the treatment of erectile dysfunction (ED) in men. Compared with traditional treatment, it has the advantage lies in the ability to treat the pathological damage of the penis in patients with ED, which provides new ideas for solving erectile dysfunction fundamentally. However, due to the special anatomical structure of the penis, the therapeutic effect of stem cells is sometimes unsatisfactory. Therefore, how to improve the effect of stem cells therapy for ED has become a new difficulty. Relevant researches on how to improve stem cell treatment of ED will be reviewed in this article.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 7","pages":"645-649"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Role of the prostate health index and its derivatives in the early screening of patients with PI-RADS score 3]. [前列腺健康指数及其衍生物在PI-RADS评分3分患者早期筛查中的作用]。
Q4 Medicine Pub Date : 2025-07-01
Tong-Qing Zhang, Qiang Fu, Hao Liu, Ying-Tao Liu, Ke-Qin Zhang

Objective: To explore the role of prostate health index (PHI) and its derivatives for early screening in patients with PI-RADS score 3 and prostate-specific antigen (PSA) levels of 4-20 μg/L.

Methods: Clinical data of 203 patients with a score of 3 on the PI-RADS v2.1 scoring system who underwent ultrasound-guided transperineal prostate aspiration biopsy from April 2021 to April 2024 from Provincial Hospital of Shandong First Medical University, Qilu Hospital of Shandong University and Weifang People's Hospital were collected. Patients who met the inclusion criteria were divided into prostate cancer (PCa) group (62 cases) and benign prostatic hyperplasia (BPH) group (141 cases). Serum total prostate-specific antigen (tPSA), serum free prostate-specific antigen (fPSA), and PSA isoform 2 (p2PSA) were routinely detected after admission. And prostate-specific antigen density (PSAD), prostate health index (PHI) and prostate health index density (PHID) were calculated with the basic personal information being collected. The efficacy of each parameter in early screening of patients with PI-RADS score of 3 and PSA level of 4-20 μg/L was assessed using ROC curve approach.

Results: There was no statistical difference in tPSA, fPSA and fPSA/tPSA between the two groups (P>0.05). There was a statistical difference in p2PSA, PSAD, PHI, PHID and age between the two groups (P<0.05). PHI (AUC=0.783 7, 95% CI: 0.711 3-0.856 1) and PHID (AUC=0.782 3, 95% CI: 0.708 3-0.856 4) showed a good predictive ability in the early screening of prostate cancer. In the clinically significant prostate cancer (csPCa) group, the ROC curve areas of PHI and PHID were 0.823 0 and 0.788 5, respectively, which showed better predictive efficacy of prediction of csPCa. The ROC curves of the combined diagnostic indexes were plotted on the basis of the independent ROC curves, and the area under the curve of PHI combined with age, p2PSA and PHID (AUC=0.843 6) was the largest and had the best predictive ability among all the combined diagnostic indexes.

Conclusion: In patients with PI-RADS score 3 and PSA level between 4 and 20 μg/L, PHI and its derivatives (PHI and PHID) provide a new way for early screening of prostate cancer compared with the traditional index tPSA, which has a high value of application in reducing the over-penetration.

目的:探讨前列腺健康指数(PHI)及其衍生物在PI-RADS评分为3分、前列腺特异性抗原(PSA)水平在4 ~ 20 μg/L的患者早期筛查中的作用。方法:收集2021年4月至2024年4月山东第一医科大学省立医院、山东大学齐鲁医院和潍坊市人民医院行超声引导下经会阴前列腺穿刺活检患者203例,PI-RADS v2.1评分为3分的临床资料。符合入选标准的患者分为前列腺癌(PCa)组(62例)和良性前列腺增生(BPH)组(141例)。入院后常规检测血清总前列腺特异性抗原(tPSA)、血清游离前列腺特异性抗原(fPSA)、PSA亚型2 (p2PSA)。收集个人基本信息,计算前列腺特异性抗原密度(PSAD)、前列腺健康指数(PHI)和前列腺健康指数密度(PHID)。采用ROC曲线法评价PI-RADS评分为3分、PSA水平为4 ~ 20 μg/L患者各参数在早期筛查中的效果。结果:两组患者tPSA、fPSA及fPSA/tPSA比较,差异均无统计学意义(P < 0.05)。结论:在PI-RADS评分为3分、PSA水平在4 ~ 20 μg/L的患者中,PHI及其衍生物(PHI和PHID)与传统指标tPSA相比,为早期筛查前列腺癌提供了一种新的方法,在减少过度渗透方面具有较高的应用价值。
{"title":"[Role of the prostate health index and its derivatives in the early screening of patients with PI-RADS score 3].","authors":"Tong-Qing Zhang, Qiang Fu, Hao Liu, Ying-Tao Liu, Ke-Qin Zhang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To explore the role of prostate health index (PHI) and its derivatives for early screening in patients with PI-RADS score 3 and prostate-specific antigen (PSA) levels of 4-20 μg/L.</p><p><strong>Methods: </strong>Clinical data of 203 patients with a score of 3 on the PI-RADS v2.1 scoring system who underwent ultrasound-guided transperineal prostate aspiration biopsy from April 2021 to April 2024 from Provincial Hospital of Shandong First Medical University, Qilu Hospital of Shandong University and Weifang People's Hospital were collected. Patients who met the inclusion criteria were divided into prostate cancer (PCa) group (62 cases) and benign prostatic hyperplasia (BPH) group (141 cases). Serum total prostate-specific antigen (tPSA), serum free prostate-specific antigen (fPSA), and PSA isoform 2 (p2PSA) were routinely detected after admission. And prostate-specific antigen density (PSAD), prostate health index (PHI) and prostate health index density (PHID) were calculated with the basic personal information being collected. The efficacy of each parameter in early screening of patients with PI-RADS score of 3 and PSA level of 4-20 μg/L was assessed using ROC curve approach.</p><p><strong>Results: </strong>There was no statistical difference in tPSA, fPSA and fPSA/tPSA between the two groups (P>0.05). There was a statistical difference in p2PSA, PSAD, PHI, PHID and age between the two groups (P<0.05). PHI (AUC=0.783 7, 95% CI: 0.711 3-0.856 1) and PHID (AUC=0.782 3, 95% CI: 0.708 3-0.856 4) showed a good predictive ability in the early screening of prostate cancer. In the clinically significant prostate cancer (csPCa) group, the ROC curve areas of PHI and PHID were 0.823 0 and 0.788 5, respectively, which showed better predictive efficacy of prediction of csPCa. The ROC curves of the combined diagnostic indexes were plotted on the basis of the independent ROC curves, and the area under the curve of PHI combined with age, p2PSA and PHID (AUC=0.843 6) was the largest and had the best predictive ability among all the combined diagnostic indexes.</p><p><strong>Conclusion: </strong>In patients with PI-RADS score 3 and PSA level between 4 and 20 μg/L, PHI and its derivatives (PHI and PHID) provide a new way for early screening of prostate cancer compared with the traditional index tPSA, which has a high value of application in reducing the over-penetration.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 7","pages":"612-618"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Symptoms and treatment of benign prostatic hyperplasia patients with upper urinary tract calculi after ureteral stent implantation]. 【输尿管支架植入术后良性前列腺增生合并上尿路结石的症状及治疗】。
Q4 Medicine Pub Date : 2025-07-01
Wei Liu, Hui Zhang, Shuang-Ning Liu, Shao-Hua Bian, Qi-Yuan Kang, Ying-Yi Li, Qiao DU, Wen-Bing Yuan, Jiang Zhu

Objective: To analyze the symptoms, diagnosis and treatment of upper urinary tract calculi patients combined with mild and moderate benign prostatic hyperplasia (BPH) after ureteral stent implantation. Methods: One hundred and six BPH patients who were hospitalized for upper urinary tract calculi and had ureteral stents retained from January 2019 to December 2022 were selected and divided into 2 weeks group and 4 weeks group according to the time of removal of ureteral stents after surgery. Their general clinical data were analyzed and compared. International Prostatic Symptom Scale (IPSS), postoperative ureteral Stent Symptom Questionnaire (USSQ), and incidence of adverse events after ureteral stent removal were recorded before and after removal. Results: The scores of IPSS were significantly increased in all patients, and symptoms in urinary tract had improved significantly after discharge (P<0.05). Compared with the 2 weeks group, the USSQ score of the 4 weeks group was significantly increased (P<0.05). And no significant adverse event was observed in the 2 weeks group after the removal of ureteral sten. Conclusion: IPSS score and USSQ score increased significantly during stent implantation in BPH patients with lithiasis. And complications increased significantly over time. Following thorough clinical assessment, early ureteral stent removal demonstrates both safety and efficacy, representing an optimal therapeutic approach in selected cases.

目的:分析输尿管支架植入术后上尿路结石合并轻、中度良性前列腺增生(BPH)的症状、诊断及治疗。方法:选取2019年1月至2022年12月因上尿路结石住院并留置输尿管支架的BPH患者106例,根据术后输尿管支架取出时间分为2周组和4周组。分析比较两组患者的一般临床资料。记录输尿管支架取出前后国际前列腺症状量表(IPSS)、输尿管支架术后症状问卷(USSQ)、输尿管支架取出后不良事件发生率。结果:所有患者IPSS评分均显著提高,出院后尿路症状明显改善(P
{"title":"[Symptoms and treatment of benign prostatic hyperplasia patients with upper urinary tract calculi after ureteral stent implantation].","authors":"Wei Liu, Hui Zhang, Shuang-Ning Liu, Shao-Hua Bian, Qi-Yuan Kang, Ying-Yi Li, Qiao DU, Wen-Bing Yuan, Jiang Zhu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Objective: To analyze the symptoms, diagnosis and treatment of upper urinary tract calculi patients combined with mild and moderate benign prostatic hyperplasia (BPH) after ureteral stent implantation. Methods: One hundred and six BPH patients who were hospitalized for upper urinary tract calculi and had ureteral stents retained from January 2019 to December 2022 were selected and divided into 2 weeks group and 4 weeks group according to the time of removal of ureteral stents after surgery. Their general clinical data were analyzed and compared. International Prostatic Symptom Scale (IPSS), postoperative ureteral Stent Symptom Questionnaire (USSQ), and incidence of adverse events after ureteral stent removal were recorded before and after removal. Results: The scores of IPSS were significantly increased in all patients, and symptoms in urinary tract had improved significantly after discharge (P<0.05). Compared with the 2 weeks group, the USSQ score of the 4 weeks group was significantly increased (P<0.05). And no significant adverse event was observed in the 2 weeks group after the removal of ureteral sten. Conclusion: IPSS score and USSQ score increased significantly during stent implantation in BPH patients with lithiasis. And complications increased significantly over time. Following thorough clinical assessment, early ureteral stent removal demonstrates both safety and efficacy, representing an optimal therapeutic approach in selected cases.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 7","pages":"608-611"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Mechanism of Qilin pills in the treatment of asthenozoospermia: Based on HPLC-MS combined with bioinformatics]. 【麒麟丸治疗弱精子症的作用机制:基于HPLC-MS结合生物信息学的研究】。
Q4 Medicine Pub Date : 2025-07-01
Chun-Ling Wang, Yu-Rong Xu, Ya-Xu Jia, Jia Liu, Li-L Huang, Bai-Hao Chen

Objective: The aim of this study is to investigate the main active substances of Qilin pills by high performance liquid chromatogre-electrostatic field orbitrap mass spectrometry (HPLC-Q-Orbitrap /MS), and explore the mechanism of its action in the treatment of asthenozoospermia by combining network pharmacology and molecular docking.

Methods: (1) Qilin pills were quantitatively and qualitatively analyzed by HPLC-Q-Orbitrap /MS. (2) The top 100 compounds in Qilin pills were screened by content analysis and SwissADME, and their targets were predicted. The asthenozoospermia targets were searched through the database. And a "protein-protein interaction" (PPI) network was constructed. KEGG and GO analysis was performed using the DAVID database. And a "drug-target-pathway" network was constructed. (3) SailVina was used for molecular docking.

Results: (1) A total of 1 275 known components were found and ranked in Qilin pills by HPLC-Q-Orbitrap /MS analysis. (2) The top 100 compounds in Qilin pills predicted a total of 1 053 targets and 184 potential therapeutic targets for asthenozoospermia. KEGG pathway analysis and GO analysis showed that the treatment of asthenozoospermia by Qilin pills may be related to the steroid hormone synthesis pathway, the response to steroid hormones, the chromosomal region of cells and the activity of steroid hydroxylase. The mechanism of Qilin pills in treating asthenozoospermia may be related to regulating the synthesis, metabolism and reaction process of sex hormone in the body. (3) The molecular docking results of its key targets (CYP19A1, ESR1, HSP90AA1, p53, HIF1α and BCL2) showed that the key active ingredients M030, M039, M043, M050, M055 and M073 of Qilin pills had spontaneous binding. It had a binding energy of less than -5 kJ /mol.

Conclusion: The material basis of Qilin pills has been explored by this study. And the mechanism of action of Qilin pills in the treatment of asthenozoospermia is highly bound to the expression and response process of steroid hormones, which provides a theoretical basis for the clinical application of Qilin pills.

目的:采用高效液相色谱-静电场轨道阱质谱法(HPLC-Q-Orbitrap /MS)研究七林丸的主要活性物质,并结合网络药理学和分子对接技术,探讨其治疗弱精子症的作用机制。方法:(1)采用HPLC-Q-Orbitrap /MS对麒麟丸进行定量定性分析。(2)通过含量分析和SwissADME对麒麟丸中前100个化合物进行筛选,并对其靶点进行预测。通过数据库检索弱精子症目标。构建了“蛋白质-蛋白质相互作用”(PPI)网络。使用DAVID数据库进行KEGG和GO分析。构建了“药物-靶标-通路”网络。(3)利用SailVina进行分子对接。结果:(1)通过HPLC-Q-Orbitrap /MS分析,共检出1 275种已知成分,并对其进行排序。(2)麒麟丸前100位化合物预测弱精子症治疗靶点1 053个,潜在治疗靶点184个。KEGG通路分析和GO分析表明,麒麟丸治疗弱精子症可能与类固醇激素合成途径、对类固醇激素的反应、细胞染色体区域和类固醇羟化酶活性有关。麒麟丸治疗弱精子症的作用机制可能与调节体内性激素的合成、代谢及反应过程有关。(3)其关键靶点(CYP19A1、ESR1、HSP90AA1、p53、HIF1α、BCL2)的分子对接结果显示,其关键活性成分M030、M039、M043、M050、M055、M073具有自发结合作用。它的结合能小于-5 kJ /mol。结论:探索了麒麟丸的物质基础。而麒麟丸治疗弱精子症的作用机制与类固醇激素的表达和反应过程高度结合,为麒麟丸的临床应用提供了理论依据。
{"title":"[Mechanism of Qilin pills in the treatment of asthenozoospermia: Based on HPLC-MS combined with bioinformatics].","authors":"Chun-Ling Wang, Yu-Rong Xu, Ya-Xu Jia, Jia Liu, Li-L Huang, Bai-Hao Chen","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to investigate the main active substances of Qilin pills by high performance liquid chromatogre-electrostatic field orbitrap mass spectrometry (HPLC-Q-Orbitrap /MS), and explore the mechanism of its action in the treatment of asthenozoospermia by combining network pharmacology and molecular docking.</p><p><strong>Methods: </strong>(1) Qilin pills were quantitatively and qualitatively analyzed by HPLC-Q-Orbitrap /MS. (2) The top 100 compounds in Qilin pills were screened by content analysis and SwissADME, and their targets were predicted. The asthenozoospermia targets were searched through the database. And a \"protein-protein interaction\" (PPI) network was constructed. KEGG and GO analysis was performed using the DAVID database. And a \"drug-target-pathway\" network was constructed. (3) SailVina was used for molecular docking.</p><p><strong>Results: </strong>(1) A total of 1 275 known components were found and ranked in Qilin pills by HPLC-Q-Orbitrap /MS analysis. (2) The top 100 compounds in Qilin pills predicted a total of 1 053 targets and 184 potential therapeutic targets for asthenozoospermia. KEGG pathway analysis and GO analysis showed that the treatment of asthenozoospermia by Qilin pills may be related to the steroid hormone synthesis pathway, the response to steroid hormones, the chromosomal region of cells and the activity of steroid hydroxylase. The mechanism of Qilin pills in treating asthenozoospermia may be related to regulating the synthesis, metabolism and reaction process of sex hormone in the body. (3) The molecular docking results of its key targets (CYP19A1, ESR1, HSP90AA1, p53, HIF1α and BCL2) showed that the key active ingredients M030, M039, M043, M050, M055 and M073 of Qilin pills had spontaneous binding. It had a binding energy of less than -5 kJ /mol.</p><p><strong>Conclusion: </strong>The material basis of Qilin pills has been explored by this study. And the mechanism of action of Qilin pills in the treatment of asthenozoospermia is highly bound to the expression and response process of steroid hormones, which provides a theoretical basis for the clinical application of Qilin pills.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 7","pages":"579-590"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Impact of altitude on NIH-CPSI scores in patients with chronic prostatitis/chronic pelvic pain syndrome]. [海拔对慢性前列腺炎/慢性盆腔疼痛综合征患者NIH-CPSI评分的影响]
Q4 Medicine Pub Date : 2025-07-01
Qiang Zhang, Qian Tang, Xu-Zhen Su, Rui-Jun Xiang, Chun-Lei Zhang, Bin Zhang, De-Hui Chang

Objective: To analyze the effect of altitude on NIH-CPSI score in patients with chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) Methods: Clinical data and the results of NIH-CPSI Questionnaire of the 321 patients with CP/CPPS at different altitudes were collected from March 2021 to March 2022. And the influence of altitudes on NIH-CPSI score of CP/CPPS was analyzed.

Result: The NIH-CPSI score of patients living at an altitude of 4 300 m was significantly higher than that of patients living at an altitude of 1 500 m and 2 200 m. The CP/CPPS patients who lived in the higher altitude had more severe symptoms of pain and urination as well as lower scores of life quality (P<0.05).

Conclusion: NIH-CPSI score increased significantly with higher altitude, indicating more severe symptoms and decreased quality of life in CP/CPPS patients. These findings highlight the need for management strategies for specific heights in patients with CP/CPPS.

目的:分析海拔对慢性前列腺炎/慢性盆腔疼痛综合征(CP/CPPS)患者NIH-CPSI评分的影响。方法:收集2021年3月至2022年3月321例不同海拔地区CP/CPPS患者的临床资料及NIH-CPSI问卷结果。并分析海拔对CP/CPPS NIH-CPSI评分的影响。结果:海拔4 300 m的患者NIH-CPSI评分显著高于海拔1 500 m和2 200 m的患者。CP/CPPS患者生活海拔越高,疼痛和排尿症状越严重,生活质量评分越低(p)。结论:NIH-CPSI评分随海拔越高而显著升高,表明CP/CPPS患者的症状越严重,生活质量越差。这些发现强调了对CP/CPPS患者特定身高的管理策略的必要性。
{"title":"[Impact of altitude on NIH-CPSI scores in patients with chronic prostatitis/chronic pelvic pain syndrome].","authors":"Qiang Zhang, Qian Tang, Xu-Zhen Su, Rui-Jun Xiang, Chun-Lei Zhang, Bin Zhang, De-Hui Chang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the effect of altitude on NIH-CPSI score in patients with chronic prostatitis/chronic pelvic pain syndrome(CP/CPPS) Methods: Clinical data and the results of NIH-CPSI Questionnaire of the 321 patients with CP/CPPS at different altitudes were collected from March 2021 to March 2022. And the influence of altitudes on NIH-CPSI score of CP/CPPS was analyzed.</p><p><strong>Result: </strong>The NIH-CPSI score of patients living at an altitude of 4 300 m was significantly higher than that of patients living at an altitude of 1 500 m and 2 200 m. The CP/CPPS patients who lived in the higher altitude had more severe symptoms of pain and urination as well as lower scores of life quality (P<0.05).</p><p><strong>Conclusion: </strong>NIH-CPSI score increased significantly with higher altitude, indicating more severe symptoms and decreased quality of life in CP/CPPS patients. These findings highlight the need for management strategies for specific heights in patients with CP/CPPS.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 7","pages":"619-624"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Statin drugs for the treatment of erectile dysfunction: An umbrella review]. [他汀类药物治疗勃起功能障碍:综述]。
Q4 Medicine Pub Date : 2025-07-01
Ze Li, Pei-Hai Zhang, Mei-Jun Liu, Tao Zhang

Objective: The aim of this study is to re-evaluate the systematic reviews and meta-analyses on statins for the treatment of erectile dysfunction (ED) and construct an umbrella review, thereby providing robust evidence-based for the clinical application of statins in ED treatment.

Methods: A comprehensive computerized search was conducted across CNKI, Wanfang Database, VIP, WOS, Embase, PubMed, and Cochrane Library databases from their inception to September 12, 2024, for all systematic reviews and meta-analyses addressing statin interventions in ED. The methodological quality, reporting quality, and evidence quality of the included studies were assessed and summarized using PRISMA 2020, AMSTAR 2, and GRADE systems.

Results: Four systematic reviews and meta-analyses were included. According to the AMSTAR 2 evaluation, one paper was rated as low quality, while the remaining three were classified as very low quality. PRISMA 2020 evaluation results indicated that the average score of the four included studies was 29, with all being of medium quality but exhibiting partial deficiencies. The proportion of fully consistent items across the four studies ranged from 52.38% to 80.95%. GRADE system tool evaluation revealed 11 outcome indicators, of which only one was rated as intermediate evidence. The remainders were categorized as low or very low evidence, with no high-quality evidence identified.

Conclusion: Statins demonstrate efficacy in treating ED. However, the current quality of relevant systematic reviews is suboptimal, with notable deficiencies in methodological, reporting, and evidential quality. Further high-quality studies are warranted to provide more reliable evidence-based medical guidance for clinical practice.

目的:本研究旨在重新评价他汀类药物治疗勃起功能障碍(ED)的系统评价和荟萃分析,构建一个总括性综述,从而为他汀类药物在ED治疗中的临床应用提供有力的循证证据。方法:全面计算机检索中国知网、万方数据库、VIP、WOS、Embase、PubMed和Cochrane图书馆数据库,从数据库建立到2024年9月12日,检索所有涉及他汀类药物干预ED的系统综述和荟萃分析。使用PRISMA 2020、AMSTAR 2和GRADE系统评估和总结纳入研究的方学质量、报告质量和证据质量。结果:纳入了四项系统综述和荟萃分析。根据AMSTAR 2评估,1篇论文被评为低质量,其余3篇被评为非常低质量。PRISMA 2020评价结果显示,纳入的4项研究平均得分为29分,均为中等质量,但存在部分不足。四项研究中完全一致条目的比例为52.38% ~ 80.95%。GRADE系统工具评价显示了11个结果指标,其中只有一个被评为中间证据。其余的被归类为低证据或极低证据,没有发现高质量的证据。结论:他汀类药物治疗ED有效。然而,目前相关系统评价的质量并不理想,在方法学、报告和证据质量方面存在明显缺陷。有必要进一步开展高质量的研究,为临床实践提供更可靠的循证医学指导。
{"title":"[Statin drugs for the treatment of erectile dysfunction: An umbrella review].","authors":"Ze Li, Pei-Hai Zhang, Mei-Jun Liu, Tao Zhang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study is to re-evaluate the systematic reviews and meta-analyses on statins for the treatment of erectile dysfunction (ED) and construct an umbrella review, thereby providing robust evidence-based for the clinical application of statins in ED treatment.</p><p><strong>Methods: </strong>A comprehensive computerized search was conducted across CNKI, Wanfang Database, VIP, WOS, Embase, PubMed, and Cochrane Library databases from their inception to September 12, 2024, for all systematic reviews and meta-analyses addressing statin interventions in ED. The methodological quality, reporting quality, and evidence quality of the included studies were assessed and summarized using PRISMA 2020, AMSTAR 2, and GRADE systems.</p><p><strong>Results: </strong>Four systematic reviews and meta-analyses were included. According to the AMSTAR 2 evaluation, one paper was rated as low quality, while the remaining three were classified as very low quality. PRISMA 2020 evaluation results indicated that the average score of the four included studies was 29, with all being of medium quality but exhibiting partial deficiencies. The proportion of fully consistent items across the four studies ranged from 52.38% to 80.95%. GRADE system tool evaluation revealed 11 outcome indicators, of which only one was rated as intermediate evidence. The remainders were categorized as low or very low evidence, with no high-quality evidence identified.</p><p><strong>Conclusion: </strong>Statins demonstrate efficacy in treating ED. However, the current quality of relevant systematic reviews is suboptimal, with notable deficiencies in methodological, reporting, and evidential quality. Further high-quality studies are warranted to provide more reliable evidence-based medical guidance for clinical practice.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 7","pages":"637-644"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145001391","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Advances in neuroimaging mechanisms of lifelong premature ejaculation based on magnetic resonance imaging]. 基于磁共振成像的终身早泄神经成像机制研究进展。
Q4 Medicine Pub Date : 2025-06-01
Da-Wei Gao, Yi-Han Jin, Da-Lin Sun, Bao-Fang Jin

Magnetic resonance imaging (MRI), as a non-invasive neuroimaging technique, has been widely employed to investigate changes in functional brain regions. In recent years, the application of MRI in the study of lifelong premature ejaculation (LPE) has progressively uncovered the pathological mechanisms underlying abnormalities in LPE-associated brain regions. These mechanisms involve brain areas associated with higher-order cognitive and decision-making regulation, sensory and perceptual processing, as well as emotional regulation and reward systems. The application and findings of MRI in the study of LPE mechanisms will be introduced in this review, with the goal of deepening our understanding of the neuroimaging-based mechanisms of LPE.

磁共振成像(MRI)作为一种非侵入性的神经成像技术,已被广泛应用于研究脑功能区域的变化。近年来,MRI在终身早泄(LPE)研究中的应用逐渐揭示了LPE相关脑区异常的病理机制。这些机制涉及与高阶认知和决策调节、感觉和知觉处理以及情绪调节和奖励系统相关的大脑区域。本文将介绍MRI在LPE机制研究中的应用和发现,旨在加深我们对LPE神经影像学机制的理解。
{"title":"[Advances in neuroimaging mechanisms of lifelong premature ejaculation based on magnetic resonance imaging].","authors":"Da-Wei Gao, Yi-Han Jin, Da-Lin Sun, Bao-Fang Jin","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Magnetic resonance imaging (MRI), as a non-invasive neuroimaging technique, has been widely employed to investigate changes in functional brain regions. In recent years, the application of MRI in the study of lifelong premature ejaculation (LPE) has progressively uncovered the pathological mechanisms underlying abnormalities in LPE-associated brain regions. These mechanisms involve brain areas associated with higher-order cognitive and decision-making regulation, sensory and perceptual processing, as well as emotional regulation and reward systems. The application and findings of MRI in the study of LPE mechanisms will be introduced in this review, with the goal of deepening our understanding of the neuroimaging-based mechanisms of LPE.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 6","pages":"552-557"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Construction and application of a standard operating procedure for urinary incontinence management in patients undergoing radical prostatectomy]. 【根治性前列腺切除术患者尿失禁管理标准操作规程的构建与应用】。
Q4 Medicine Pub Date : 2025-06-01
Na Yang, Fan Yang, Qiu-Xia Qin, Yuan Zhang

Objective: To explore the effect of evidence-based standardized procedures (SOP) on urinary incontinence management in patients with radical prostatectomy.

Methods: Sixty-three patients who underwent radical prostatectomy from October 2022 to September 2023 were included in the control group. And 63 patients who underwent radical prostatectomy from October 2023 to September 2024 were included in the observation group. The patients in the control group received routine perioperative care. As an addition, the SOP on urinary incontinence management was performed in the patients of observation group. The incidence of urinary incontinence, severity of urinary incontinence (1h urine pad test), quality of life (Incontinence Quality of Life Questionnaire) and comfort level (General Comfort Question) of the two groups were compared after 3 and 6 months of surgery.

Results: The incidence of urinary incontinence at 3 and 6 months after operation in the observation group was 36.51% and 19.05%, respectively, which were lower than those (53.97% and 38.10%) of the control group, respectively. And the incidence rates of the two groups decreased significantly (P<0.05).The score of life quality after 3 months of operation was (56.17±12.75) in the control group, which was lower than that (70.41±14.50) of the observation group. The 3-month postoperative comfort score was (52.73±11.26) in the control group and (63.49±13.52) in the observation group. The 6-month postoperative incontinence quality of life score was (64.70±11.38) in the control group and (85.41±12.04) in the observation group. And the 6-month postoperative comfort score was (60.96±8.04) in the control group and (83.49±12.04) in the observation group. The quality of life and comfort scores of the two groups 6 months after operation were significantly improved than those 3 months after operation, and the improvement of the observation group was more obvious than that of the control group (P<0.05). There were significant differences in the degree of urinary incontinence between the two groups at 3 months and 6 months after operation (P<0.05).

Conclusion: SOP management for the patients underwent radical prostatectomy can be an effective method for reducing the incidence of postoperative urinary incontinence, which promotes the recovery of postoperative urinary control.

目的:探讨循证标准化程序(SOP)在根治性前列腺切除术患者尿失禁管理中的作用。方法:将2022年10月至2023年9月行根治性前列腺切除术的患者63例作为对照组。观察组为2023年10月至2024年9月行根治性前列腺切除术的患者63例。对照组患者接受常规围手术期护理。在此基础上,对观察组患者进行尿失禁处理SOP。比较两组患者术后3个月和6个月的尿失禁发生率、尿失禁严重程度(1h尿垫试验)、生活质量(尿失禁生活质量问卷)和舒适度(一般舒适度问题)。结果:观察组术后3、6个月尿失禁发生率分别为36.51%、19.05%,低于对照组(53.97%、38.10%)。结论:对根治性前列腺切除术患者进行SOP管理可有效降低术后尿失禁的发生率,促进术后尿控制的恢复。
{"title":"[Construction and application of a standard operating procedure for urinary incontinence management in patients undergoing radical prostatectomy].","authors":"Na Yang, Fan Yang, Qiu-Xia Qin, Yuan Zhang","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To explore the effect of evidence-based standardized procedures (SOP) on urinary incontinence management in patients with radical prostatectomy.</p><p><strong>Methods: </strong>Sixty-three patients who underwent radical prostatectomy from October 2022 to September 2023 were included in the control group. And 63 patients who underwent radical prostatectomy from October 2023 to September 2024 were included in the observation group. The patients in the control group received routine perioperative care. As an addition, the SOP on urinary incontinence management was performed in the patients of observation group. The incidence of urinary incontinence, severity of urinary incontinence (1h urine pad test), quality of life (Incontinence Quality of Life Questionnaire) and comfort level (General Comfort Question) of the two groups were compared after 3 and 6 months of surgery.</p><p><strong>Results: </strong>The incidence of urinary incontinence at 3 and 6 months after operation in the observation group was 36.51% and 19.05%, respectively, which were lower than those (53.97% and 38.10%) of the control group, respectively. And the incidence rates of the two groups decreased significantly (P<0.05).The score of life quality after 3 months of operation was (56.17±12.75) in the control group, which was lower than that (70.41±14.50) of the observation group. The 3-month postoperative comfort score was (52.73±11.26) in the control group and (63.49±13.52) in the observation group. The 6-month postoperative incontinence quality of life score was (64.70±11.38) in the control group and (85.41±12.04) in the observation group. And the 6-month postoperative comfort score was (60.96±8.04) in the control group and (83.49±12.04) in the observation group. The quality of life and comfort scores of the two groups 6 months after operation were significantly improved than those 3 months after operation, and the improvement of the observation group was more obvious than that of the control group (P<0.05). There were significant differences in the degree of urinary incontinence between the two groups at 3 months and 6 months after operation (P<0.05).</p><p><strong>Conclusion: </strong>SOP management for the patients underwent radical prostatectomy can be an effective method for reducing the incidence of postoperative urinary incontinence, which promotes the recovery of postoperative urinary control.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 6","pages":"512-518"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical efficacy of Wenshen Chushi Decoction combined with LIPUS on erectile dysfunction with renal deficiency and phlegm-dampness syndrome]. [温参散食汤联合利普司治疗肾虚痰湿型勃起功能障碍的临床疗效]。
Q4 Medicine Pub Date : 2025-06-01
Wen-Xiong Zhu, Yi-Feng Yuan, Tao Liu, Bo Li, Liu-Ya Long, Qi-Hua Chen, Ju-Qiao He

Objective: To explore the clinical efficacy of Wenshen Chushi Decoction combined with low intensity pulsed ultrasound (LIPUS) on erectile dysfunction (ED) caused by renal deficiency and phlegm-dampness syndrome.

Methods: One hundred and twenty ED patients were included from the Department of Andrology in the First Hospital of Hunan University of Traditional Chinese Medicine. The patients in control group were treated with Wenshen Chushi Decoction. While the patients in observation group were treated with Wenshen Chushi Decoction combined with LIPUS for 8 consecutive weeks. After the treatment, the efficacy was evaluated using the International Index of Erectile Function-5 (IIEF-5) score, Penile Flow Index (PFI), Traditional Chinese Medicine Syndrome Score, Self-Rating Depression Scale (SDS) score, and Self-Rating Anxiety Scale (SAS) score. Safety was also observed. And the efficacy was followed up 4 weeks after the end of treatment.

Results: Fifty-seven cases were enrolled into control group finally with 55 cases in the treatment group. After the treatment, all the patients in both of groups showed an improvement in IIEF-5 scores (P<0.01). Compared with the control group (19.09 ± 2.22), the IIEF-5 score in observation group (20.42 ± 2.39) increased significantly (P<0.01). After the treatment, the scores of PFI, TCM syndrome and SDS in both groups decreased (P<0.01, P<0.05, P<0.01). Compared with the control group ([3.77 ± 1.21], [9.91 ± 1.71] and [39.88 ± 2.63] points), the observation group ([2.92 ± 1.08], [4.78 ± 1.45], and [34.51 ± 2.09] points) showed a more significant decrease (P<0.01). There was no significant difference in total effective rate between the two groups (P>0.05). During follow-up, the IIEF-5 scores of both groups of patients were higher than those before (P<0.05, P<0.01), and the observation group score was higher than that in the control group ([17.15 ± 3.37] vs [13.63 ± 1.96], P<0.01). No adverse reaction and abnormality of indicators occurred in both of two groups.

Conclusion: Wenshen Chushi Decoction has a significant therapeutic effect on ED caused by renal deficiency and phlegm-dampness syndrome. It can not only improve the quality of erection, but also improve the physical and mental symptoms associated with ED, which makes therapeutic effect lasting longer.

目的:探讨文参解湿汤联合低强度脉冲超声(LIPUS)治疗肾虚痰湿型勃起功能障碍(ED)的临床疗效。方法:选取湖南中医药大学第一医院男科急诊患者120例。对照组患者给予温参散食汤治疗。观察组患者采用文参出窍汤联合LIPUS治疗,连续8周。治疗后采用国际勃起功能指数-5 (IIEF-5)评分、阴茎流量指数(PFI)、中医证候评分、抑郁自评量表(SDS)评分、焦虑自评量表(SAS)评分评价疗效。还观察了安全性。治疗结束后4周随访疗效。结果:最终纳入对照组57例,治疗组55例。治疗后,两组患者IIEF-5评分均有改善(P0.05)。随访期间,两组患者IIEF-5评分均高于同组治疗前(p)。结论:文参散食汤治疗肾虚痰湿型ED疗效显著。它不仅可以改善勃起质量,还可以改善与ED相关的身心症状,使治疗效果更持久。
{"title":"[Clinical efficacy of Wenshen Chushi Decoction combined with LIPUS on erectile dysfunction with renal deficiency and phlegm-dampness syndrome].","authors":"Wen-Xiong Zhu, Yi-Feng Yuan, Tao Liu, Bo Li, Liu-Ya Long, Qi-Hua Chen, Ju-Qiao He","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>To explore the clinical efficacy of Wenshen Chushi Decoction combined with low intensity pulsed ultrasound (LIPUS) on erectile dysfunction (ED) caused by renal deficiency and phlegm-dampness syndrome.</p><p><strong>Methods: </strong>One hundred and twenty ED patients were included from the Department of Andrology in the First Hospital of Hunan University of Traditional Chinese Medicine. The patients in control group were treated with Wenshen Chushi Decoction. While the patients in observation group were treated with Wenshen Chushi Decoction combined with LIPUS for 8 consecutive weeks. After the treatment, the efficacy was evaluated using the International Index of Erectile Function-5 (IIEF-5) score, Penile Flow Index (PFI), Traditional Chinese Medicine Syndrome Score, Self-Rating Depression Scale (SDS) score, and Self-Rating Anxiety Scale (SAS) score. Safety was also observed. And the efficacy was followed up 4 weeks after the end of treatment.</p><p><strong>Results: </strong>Fifty-seven cases were enrolled into control group finally with 55 cases in the treatment group. After the treatment, all the patients in both of groups showed an improvement in IIEF-5 scores (P<0.01). Compared with the control group (19.09 ± 2.22), the IIEF-5 score in observation group (20.42 ± 2.39) increased significantly (P<0.01). After the treatment, the scores of PFI, TCM syndrome and SDS in both groups decreased (P<0.01, P<0.05, P<0.01). Compared with the control group ([3.77 ± 1.21], [9.91 ± 1.71] and [39.88 ± 2.63] points), the observation group ([2.92 ± 1.08], [4.78 ± 1.45], and [34.51 ± 2.09] points) showed a more significant decrease (P<0.01). There was no significant difference in total effective rate between the two groups (P>0.05). During follow-up, the IIEF-5 scores of both groups of patients were higher than those before (P<0.05, P<0.01), and the observation group score was higher than that in the control group ([17.15 ± 3.37] vs [13.63 ± 1.96], P<0.01). No adverse reaction and abnormality of indicators occurred in both of two groups.</p><p><strong>Conclusion: </strong>Wenshen Chushi Decoction has a significant therapeutic effect on ED caused by renal deficiency and phlegm-dampness syndrome. It can not only improve the quality of erection, but also improve the physical and mental symptoms associated with ED, which makes therapeutic effect lasting longer.</p>","PeriodicalId":24012,"journal":{"name":"中华男科学杂志","volume":"31 6","pages":"519-525"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144817672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华男科学杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1